USANA Health Sciences (NYSE:USNA) Stock Price Up 4.3% Following Better-Than-Expected Earnings

USANA Health Sciences, Inc. (NYSE:USNA - Get Free Report) shot up 4.3% during mid-day trading on Wednesday following a better than expected earnings announcement. The company traded as high as $36.10 and last traded at $35.97. 16,007 shares changed hands during trading, a decline of 80% from the average session volume of 79,591 shares. The stock had previously closed at $34.48.

The company reported $0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.49 by $0.07. USANA Health Sciences had a return on equity of 11.13% and a net margin of 6.29%. The firm had revenue of $200.22 million for the quarter, compared to the consensus estimate of $208.45 million. During the same quarter last year, the business posted $0.59 EPS.

Wall Street Analysts Forecast Growth

USNA has been the topic of several recent research reports. StockNews.com downgraded USANA Health Sciences from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, July 24th. DA Davidson lowered their target price on USANA Health Sciences from $38.00 to $35.00 and set a "neutral" rating on the stock in a research report on Wednesday.

Insider Activity at USANA Health Sciences

In related news, insider Paul A. Jones sold 6,266 shares of USANA Health Sciences stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $38.38, for a total value of $240,489.08. The transaction was disclosed in a filing with the SEC, which is available at this link. In other USANA Health Sciences news, Director John Turman Fleming sold 1,000 shares of the business's stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $44.43, for a total transaction of $44,430.00. Following the transaction, the director now owns 2,503 shares of the company's stock, valued at $111,208.29. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Paul A. Jones sold 6,266 shares of the business's stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $38.38, for a total value of $240,489.08. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 7,940 shares of company stock valued at $311,670. 0.33% of the stock is owned by insiders.

Hedge Funds Weigh In On USANA Health Sciences

Institutional investors have recently bought and sold shares of the business. Pzena Investment Management LLC boosted its holdings in shares of USANA Health Sciences by 24.4% during the second quarter. Pzena Investment Management LLC now owns 976,633 shares of the company's stock worth $44,183,000 after acquiring an additional 191,289 shares during the period. Pacer Advisors Inc. boosted its holdings in shares of USANA Health Sciences by 14.3% during the second quarter. Pacer Advisors Inc. now owns 467,352 shares of the company's stock worth $21,143,000 after acquiring an additional 58,597 shares during the period. Allspring Global Investments Holdings LLC boosted its holdings in shares of USANA Health Sciences by 14,068.2% during the third quarter. Allspring Global Investments Holdings LLC now owns 38,821 shares of the company's stock worth $1,472,000 after acquiring an additional 38,547 shares during the period. Assenagon Asset Management S.A. boosted its holdings in shares of USANA Health Sciences by 32.9% during the second quarter. Assenagon Asset Management S.A. now owns 109,252 shares of the company's stock worth $4,943,000 after acquiring an additional 27,053 shares during the period. Finally, Deerfield Management Company L.P. Series C boosted its holdings in shares of USANA Health Sciences by 297.0% during the second quarter. Deerfield Management Company L.P. Series C now owns 29,742 shares of the company's stock worth $1,346,000 after acquiring an additional 22,251 shares during the period. Institutional investors and hedge funds own 54.25% of the company's stock.

USANA Health Sciences Stock Up 6.1 %

The firm has a market capitalization of $696.89 million, a P/E ratio of 11.31, a PEG ratio of 1.20 and a beta of 0.89. The firm has a 50 day moving average of $38.02 and a 200-day moving average of $42.59.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.